ASH 2023 | Managing the side effects associated with BTKi treatment for CLL
Danielle Brander, MD, Duke University School of Medicine, Durham, NC, discusses the challenge of side effects and cumulative toxicities associated with BTK inhibitor (BTKi) treatment in patients with chronic lymphocytic leukemia (CLL). The first-generation BTKi ibrutinib is associated with a higher incidence of side effects than second-generation BTKi’s acalabrutinib and zanubrutinib, meaning that they may be a better alternative in patients who experience adverse events on ibrutinib. Dr Brander highlights that management of side effects, possible dose reduction, or switching to an alternative BTKi means that patients do not have to discontinue treatment or switch to a different class of agents. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Genentech, Pharmacyclics, AbbVie
Site PI clinical trial (grant paid to institution): Genentech, ArQule/Merck, Ascentage, Pharmacyclics, AbbVie, AstraZeneca/Acerta, TG Therapeutics, Novartis, NeWave, MEI Pharma, DTRM, Catapult, Juno/Celgene/BMS, Beigene
Research Funding: Genentech, ArQule/Merck, Ascentage, Pharmacyclics, AbbVie, AstraZeneca/Acerta, TG Therapeutics, Novartis, NeWave, MEI Pharma, DTRM, Catapult, Juno/Celgene/BMS, Beigene
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for NCCN panel member CLL/SLL and HCL, informCLL registry steering committee: Pharmacyclics
Core registry steering committee: AbbVie
Alliance in Clinical Trials- Leukemia committee member & Trial Champion of S1925: CLL Society
